{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:32:38Z","timestamp":1785148358120,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"DOI":"10.7759\/cureus.110375","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T02:44:18Z","timestamp":1780800258000},"source":"Crossref","is-referenced-by-count":1,"title":["Sodium-Glucose Linked Transporter-2 (SGLT-2) Inhibitor-Associated Unmasking of Myasthenia Gravis in a Patient With Undiagnosed Thymic Follicular Hyperplasia: The First Reported Case"],"prefix":"10.7759","author":[{"given":"Asad","family":"Waqar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okasha","family":"Zulfiqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Favour  K","family":"Mbakwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Mohayy Ud Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips WD","year":"2016","unstructured":"Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016, 5:F1000 Faculty Rev-1513. 10.12688\/f1000research.8206.1","journal-title":"F1000Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser L","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021, 10:2235. 10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders DB","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al.. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016, 87:419-25. 10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/25151355251324374","article-title":"Pembrolizumab-induced myasthenia gravis with isolated diaphragmatic involvement in a lung cancer patient: a case report","volume":"13","author":"Mouratidou N","year":"2025","unstructured":"Mouratidou N, Papadopoulos D, Vrouvaki I, Skouras V, Katsenos S. Pembrolizumab-induced myasthenia gravis with isolated diaphragmatic involvement in a lung cancer patient: a case report. Ther Adv Vaccines Immunother. 2025, 13:25151355251324374. 10.1177\/25151355251324374","journal-title":"Ther Adv Vaccines Immunother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70159","article-title":"Dapagliflozin-associated bullous pemphigoid","volume":"65","author":"Feng X","year":"2026","unstructured":"Feng X, Wei M, Li J, et al.. Dapagliflozin-associated bullous pemphigoid. Int J Dermatol. 2026, 65:1078-80. 10.1111\/ijd.70159","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/life13081715","article-title":"D-penicillamine-induced myasthenia gravis-a probable complication of Wilson's disease treatment-a case report and systematic review of the literature","volume":"13","author":"Antos A","year":"2023","unstructured":"Antos A, Cz\u0142onkowska A, Bembenek J, Kurkowska-Jastrz\u0119bska I, Litwin T. D-penicillamine-induced myasthenia gravis-a probable complication of Wilson's disease treatment-a case report and systematic review of the literature. Life (Basel). 2023, 13:1715. 10.3390\/life13081715","journal-title":"Life (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1769013","article-title":"Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database","volume":"17","author":"Cao L","year":"2026","unstructured":"Cao L, Wang Y, Dai P, Li X. Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database. Front Immunol. 2026, 17:1769013. 10.3389\/fimmu.2026.1769013","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2341","article-title":"Sotalol-induced generalized and ocular myasthenia gravis","volume":"7","author":"Sharifkazemi M","year":"2019","unstructured":"Sharifkazemi M, Ziya F. Sotalol-induced generalized and ocular myasthenia gravis. Clin Case Rep. 2019, 7:1831-2. 10.1002\/ccr3.2341","journal-title":"Clin Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.02.1435","article-title":"Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers","volume":"9","author":"Lee SA","year":"2024","unstructured":"Lee SA, Riella LV. Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers. Kidney Int Rep. 2024, 9:1601-13. 10.1016\/j.ekir.2024.02.1435","journal-title":"Kidney Int Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493768-sodium-glucose-linked-transporter-2-sglt-2-inhibitor-associated-unmasking-of-myasthenia-gravis-in-a-patient-with-undiagnosed-thymic-follicular-hyperplasia-the-first-reported-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T02:44:19Z","timestamp":1780800259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493768-sodium-glucose-linked-transporter-2-sglt-2-inhibitor-associated-unmasking-of-myasthenia-gravis-in-a-patient-with-undiagnosed-thymic-follicular-hyperplasia-the-first-reported-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.110375","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}